Page 5 - Multiple Sclerosis Relapse News Today

Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.

The statement concludes that COVID-19 vaccines are safe for patients with multiple sclerosis and that most MS patients gain the same protection as the general population. But there are exceptions.

Patients who developed secondary progressive MS at 20 years had more cortical lesions at baseline than patients with clinically isolated syndrome, relapsing-remitting MS, or primary progressive MS.